(Q35043366)

6 August 2017

title

Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment (English)

1 reference

6 August 2017

Suphat Subongkot

1

1 reference

6 August 2017

David Frame

series ordinal

2

1 reference

6 August 2017

William Leslie

series ordinal

3

1 reference

6 August 2017

Deborah Drajer

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

23

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

9-28

1 reference

6 August 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

COX-2 in large bowel cancer: a one-sided story

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandins and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

The production of prostanoids in human cancers, and their implications for tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandins and human lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandin-like material extracted from squamous carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandins, their inhibitors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Nonsteroidal antiinflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

COX-2: a target for colon cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Generation of mutagens during arachidonic acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase regulates angiogenesis induced by colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Role of cyclooxygenases in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Interactions of PGH synthase isozymes-1 and -2 with NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

The role of cyclooxygenase-2 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Carcinogen substrate specificity of human COX-1 and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

The multistep nature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Aspirin use and reduced risk of fatal colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Primary chemoprevention of familial adenomatous polyposis with sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Regulation of cyclooxygenase-2 pathway by HER2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Overexpression of cyclooxygenase-2 protein is less frequent in gastric cancers with microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Non-steroidal anti-inflammatory drugs and bladder cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of cyclooxygenase 2 by prostaglandin E(2) in human endometrial adenocarcinoma cell line HEC-1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

COX-2 in cancer--a player that's defining the rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Aspirin and reduced risk of esophageal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Oral mucosal tumor inhibition by ibuprofen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenases as the principal targets for the actions of NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Colorectal cancer and nonsteroidal anti-inflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Combinatorial chemoprevention of intestinal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Indomethacin interferes with epidermal growth factor binding and proliferative response of gastric KATO III cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.1.9.31916

10.1592/PHCO.23.1.9.31916

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference